The treatment was approved in 2024 for chronic graft-vs-host disease after failure of at least 2 prior lines of systemic therapy in patients weighing at least 40kg. The Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback